DuoBodyCD3xCD20

DuoBodyCD3xCD20 is a bispecific antibody generated using the DuoBody platform, designed to bind CD3 on T lymphocytes and CD20 on B cells. By engaging both targets, the molecule redirects cytotoxic T cells to CD20-expressing B cells, with the aim of promoting targeted cell killing in CD20-positive malignancies. The approach combines a single IgG-like molecule with dual specificity, potentially enabling more precise immune engagement than conventional monoclonal antibodies.

Structure and production are based on the DuoBody technology, which uses engineered interfaces to promote correct heterodimer formation (knobs-into-holes) and generate an IgG-like bispecific. The CD3- and CD20-binding arms are integrated into one molecule, allowing simultaneous dual binding. The Fc region may be engineered to modulate half-life and effector functions, depending on the development program and safety considerations.

Clinical development and status for DuoBodyCD3xCD20 have included preclinical characterization and early-phase clinical evaluations. Studies typically assess safety and tolerability, pharmacokinetics, dose escalation, and preliminary antitumor activity. The target indication is predominantly CD20-positive B-cell malignancies, such as non-Hodgkin lymphoma and related disorders, where T-cell redirected cytotoxicity represents a therapeutic strategy. As with other T-cell engaging bispecifics, ongoing research addresses efficacy, potential toxicities such as cytokine-related effects, and optimal dosing regimens.

In summary, DuoBodyCD3xCD20 exemplifies a bispecific, IgG-like antibody approach aiming to harness T cells to destroy CD20-expressing B cells through a single molecular scaffold.